Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single‐arm, open‐label, phase 3 trial

BACKGROUND AND AIM: This single‐arm, open‐label, multicenter, phase 3 trial evaluated the efficacy and safety of seraprevir, an hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) inhibitor, combined with sofosbuvir for treating Chinese patients with chronic HCV infection without cirrhosis....

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Fei, Wen, Xiaoyu, Wen, Xiaofeng, Wang, Xiaozhong, Wu, Guicheng, Lin, Shide, Wang, Li, Xing, Huichun, Yan, Xuebing, Zheng, Sujun, Ning, Qin, Wang, Zheng, Zhang, Liaoyun, Lin, Jianmei, Tong, Zhaowei, Huang, Chengyu, Su, Minghua, Tong, Lixin, Jia, Jidong, Xin, Yongning, Zhu, Qingjing, Wang, Jing, Chen, Li, Li, Xiaowen, Wu, Xuegang, Niu, Duan, Liu, Quan, Wei, Wei, Zhang, Yuexin, Li, Guangming, Niu, Junqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Trials and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518536/
https://www.ncbi.nlm.nih.gov/pubmed/33491236
http://dx.doi.org/10.1111/jgh.15412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518536/
https://www.ncbi.nlm.nih.gov/pubmed/33491236
http://dx.doi.org/10.1111/jgh.15412

Ejemplares similares